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Route of administration is well-known to impact factors ranging from absorption and
distribution, up through the subjective effects of active ingredients. Different routes of
administration confer specific advantages, such as more rapid absorption resulting
from intravenous injection, or increased convenience with oral administration, but a
combination of both rapid and convenient delivery is highly desirable. QuickStrip™ was
designed as a rapidly dissolving thin film matrix that contains active ingredients, which
may be promising for rapid and convenient delivery via the oral mucosa. To assess the
delivery of QuickStrip™, we administered the well-characterized active ingredient caffeine
to mice and compared QuickStrip™ to standard oral gavage delivery at an equivalent
dose of 20 mg kg-1. Using HPLC assessment of serum concentrations of caffeine, we
found that QuickStrip™ delivery resulted in higher serum levels of caffeine at 1, 10, and
30 min following administration compared to gavage. QuickStrip™ also produced greater
bioavailability compared to gavage, as demonstrated by area under the curve analysis.
Caffeine delivered by QuickStrip™ produced robust behavioral activation of locomotion,
consistent with gavage caffeine. Electroencephalographic (EEG) assessment of central
nervous system effects demonstrated that both gavage and QuickStrip™ caffeine
produced suppression of delta and theta, consistent with prior literature on the effects
of caffeine. In addition, QuickStrip™ produced a more rapid onset of EEG suppression,
supporting the more rapid absorption demonstrated in the serum studies. Collectively,
these studies suggest that QuickStrip™ may provide a balance between convenience
and rapid onset, offering new options for delivery of therapeutics.
Keywords: transmucosal, buccal, bioavability, therapeutic delivery, caffeine (1, 3, 7-trimethyl-1h-purine-2)

INTRODUCTION
Route of administration is well-known to dramatically affect the absorption, distribution, and
metabolism, as well as the physiological and behavioral responses to therapeutics. Delivery of significant
concentrations of active medicinal ingredients to a target tissue is often a substantial barrier to
therapeutic efficacy and hampers the development of novel therapeutics. Drug delivery via intravenous
(i.v.) injection is known to permit relatively rapid access to the nervous system, allowing onset of
therapeutic effects to also be rapid. However, i.v. injection is limited in clinical application of therapeutics
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by ease of use and risks of injury and infection. Administration via
injection more generally is known to be frightening and painful and
can negatively impact patient compliance (Spain et al., 2016). Oral
administration is convenient, yet it typically has a very slow onset
of therapeutic effects, and drug potency can be lost because of the
action of the digestive system and/or first pass metabolism (Patel
et al., 2011; Satheesh Madhav et al., 2012). Novel orodispersible
tablets have helped to circumvent some of these issues; however,
patient convenience and compliance could still be improved by
advances in oral delivery (Reiner et al., 2010). In particular, oral
tablet delivery can be challenging for children, the elderly, and
severely ill populations, such as those suffering from mucositis
following chemotherapy treatment (Reiner et al., 2010).
Absorption of drugs across the buccal or sublingual mucosae
is an attractive alternative to standard oral administration
because it can bypass first pass metabolism in the liver as well
as degradation in the digestive tract (Shojaei, 1998; Patel et al.,
2011; Satheesh Madhav et al., 2012). The buccal and sublingual
mucosae both receive abundant blood supply and have a relatively
high permeability, allowing drugs to enter and act rapidly (Pather
et al., 2008; Patel et al., 2011; Satheesh Madhav et al., 2012).
Important practical applications for administration via the oral
mucosa include emergency situations where rapid administration
by nonskilled personnel could be life saving, in unconscious
patients where swallowing is impaired, and in young children,
the elderly, and the severely ill. Administration via the oral
mucosa also does not require water to administer as an oral tablet
would (Reiner et al., 2010). Despite the rationale to develop these
methods of delivery, some challenges are still present in buccal or
sublingual administration, such as the characteristics of the oral
cavity, including pH, enzymatic activity, and permeability of the
mucosa (Rathbone et al., 1994; Patel et al., 2011). Improvements
to the buccal or sublingual delivery substrate could potentially
further speed absorption and distribution of active ingredients.
To advance the feasibility and efficacy of drug delivery via the
oral mucosa, we have examined a novel delivery device consisting
of micronized active ingredients incorporated into a therapeutic
thin film matrix known as QuickStrip™. This new delivery
device has the potential to capitalize on the convenience of oral
administration yet allow rapid absorption into the bloodstream
and rapid onset of therapeutic effects.
In the present study, we examined the efficacy of therapeutics
delivered via QuickStrip™ compared to standard oral
administration using a well-known active ingredient, caffeine.
Caffeine was administered at 20 mg kg-1 via oral gavage or
QuickStrip™ delivery to wild-type C57Bl6J mice, followed by
HPLC analysis of blood serum caffeine concentrations at multiple
time points, as well as behavioral and electroencephalographic
(EEG) assessment of physiological effects. We found that caffeine
delivered via QuickStrip™ resulted in significantly higher
concentrations of caffeine in the serum compared to standard oral
gavage as quickly as 1 min following administration and resulted in
substantially larger area under the curve (AUC). We next examined
the behavioral response to QuickStrip™ caffeine and observed the
well-established behavioral response of motor activation. In the
last set of experiments, we used EEG as a biomarker for access to
the central nervous system and found that caffeine delivery via
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QuickStrip™ produced a very rapid alteration in EEG activity
patterns compared to standard oral gavage.

METHODS
Animals. Animals were cared for according to the NIH Guide
for the Care and Use of Laboratory Animals (National Research
Council (US) Committee for the Update of the Guide for the
Care and Use of Laboratory Animals, 2011), and protocols were
approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of Nevada Las Vegas. Animals were
group housed on a 12:12-h light-dark schedule in a humidityand temperature-controlled room.
Caffeine Administration. Caffeine was prepared as a
2 mg ml-1 solution in deionized distilled water or as the active
ingredient micronized within the QuickStrip™ film substrate to
deliver 20 mg kg-1 caffeine. Mice were weighed the morning of the
experiment to calculate dose. Oral gavage was performed using
a specialized gavage needle (Sigma-Aldrich) affixed to a 1-ml
syringe (Sigma-Aldrich). Briefly, animals were gently restrained,
and the gavage was carefully passed through the mouth, down to
the depth of the last rib (~stomach). QuickStrip™ caffeine thin
films were obtained from Rapid Dose Therapeutics Corp. The
area of the strip was calculated to achieve 20 mg kg-1 based on the
weight of the mouse. To administer the strip, animals were gently
restrained, and the strip was placed against the buccal tissue and
held in place with forceps until softened. As a vehicle control, we
also administered deionized distilled water via gavage.
Cardiac Puncture and Serum Preparation. Animals were
deeply anesthetized with isoflurane and restrained. Cardiac
puncture was performed at specific time points (1, 5, 10, 30, and
60 min; n = 5 per time point, per administration group) following
administration by trained personnel by inserting a needle (Sarstedt)
affixed with a serum vacutainer (Sarstedt) directly into the heart.
Once sufficient sample was obtained, mice were sacrificed. Whole
blood was allowed to clot at room temperature for 30 min and then
spun at 5,000 x g to obtain serum samples. Serum was pipetted
off and stored at -80°C until HPLC analysis (Cyprotex). Serum
concentrations of caffeine were compared at each time point
using t-test, and graphs were plotted as box plots to display the
distribution of the data (SigmaPlot). To examine AUC, scatterplots
were generated, and AUC analysis was run using SigmaPlot.
Behavior. The open-field apparatus was based on that used
in the EMPReSS resource and was 44 cm × 44 cm (Brown
et al., 2005). Mice were habituated to the testing room for 1 h
before behavioral analysis. Animals were administered either 20
mg kg-1 caffeine via gavage (n = 8) or QuickStrip™ film (n = 6)
or gavage with a vehicle control solution (n = 7). Immediately
after administration, animals were placed into the open field for
60 min of free exploration. In the prehabituated studies, mice
were first habituated to the open-field arena for 60 min, followed
by administration of either 20 mg kg-1 caffeine via gavage (n = 5)
or QuickStrip™ film (n = 4). Immediately after administration,
animals were placed into the open field for an additional 60 min of
free exploration. Open-field behavior of mice was assessed using
the ANY-maze tracking analysis on video recordings taken from
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above the open field. Paths were plotted from x, y coordinates,
and heat maps were generated using MatLab. Speed and distance
measures were compared using ANOVA (one way, average
distance and average speed; two-way repeated measures, distance
traveled over time), and graphs were plotted as mean ± standard
error (SigmaPlot).
Electroencephalography. EEG and electromyography (EMG)
electrodes were implanted under isoflurane anesthesia. Two
channels of EEG were recorded bilaterally from the frontal cortex,
and ground is supplied by placement in the caudal parietal area. A
total of 11 mice were used in the EEG studies, divided randomly
into gavage (n = 4) or QuickStrip™ (n = 7) groups. EEG data
before administration were pooled to provide baseline (n = 11),
allowing the same animals to be used as their own control. After
a minimum of 7 days of postoperative recovery, EEG activity was
recorded at a sampling rate of 1,000 Hz using the Pinnacle system
for mouse during the dark phase of the cycle. Mice were first
acclimatized to the recording chamber and preamplifier for 1 h,
then recorded for 1 h of baseline. During baseline recordings, sleep
was suppressed or interrupted by introduction of novel objects as
necessary. After 1 h of baseline, mice were administered 20 mg kg-1
caffeine via either gavage or QuickStrip™. Recordings proceeded
for 1 h following administration. Results were quantified using
SleepSign and MatLab. Transformed data were parsed into spectral
frequency divisions (Hines et al., 2018) according to the following
limits: δ-0.5–4.0 Hz, θ-4.5–8 Hz, α-8.5–13 Hz, β-13.5–30, γ-30.5–
100 Hz (Drinkenburg et al., 2015). Spectral analysis compared 1 h
of baseline to 1 h postadministration. Time to suppression analysis
was performed by measuring the time from drug administration
to first suppressed peak, as marked by a change in power of greater
than 2 standard deviations from the mean baseline. Results were
analyzed using ANOVA (one way, spectral band normalized
power and time to suppression; two-way repeated measures, FFT
spectral analysis), and graphs were plotted as mean ± standard
error (SigmaPlot).

in comparison to gavage (7,275.000 ± 643.907 ng ml-1; p = 0.0266;
9,129.400 ± 738.533 ng ml-1; p = 0.00170; Figures 1D, E). No
significant difference was detected at 5 min between gavage
and QuickStrip™ caffeine (13,919.400 ± 1,913.372 ng ml-1;
10,294.000 ± 1,657.015 ng ml-1; p = 0.0950; Figure 1C), and by
60 min, the serum concentration produced by QuickStrip™
(5,115.800 ± 512.726 ng ml-1) fell below that produced by gavage
(7,068.200 ± 523.130 ng ml-1; p = 0.0143; Figure 1F). These results
demonstrate that QuickStrip™ produced more rapid delivery of
the active ingredient, caffeine, compared to oral administration.

Greater Bioavailability With QuickStrip™
Administration of Caffeine

In addition to rapid delivery, the QuickStrip™ substrate has the
potential to deliver greater overall serum concentrations of active
ingredient compared to standard oral administration. To assess the
overall bioavailability of caffeine, we analyzed the HPLC results
from both oral gavage and QuickStrip™ for the AUC. Serum
results across the time course were plotted for both gavage and
QuickStrip™ caffeine (Figure 1G,H). Plots reveal a second rise in
serum concentration at 30 min post QuickStrip™ administration
(Figure 2H). AUC analysis of gavage administration resulted in a
value of 487,631.9, whereas AUC analysis of QuickStrip™ resulted
in a value of 631,563.5 (Figure 1I), resulting in a difference
of 1,439,931.6 between the calculated AUCs. These results
demonstrate that QuickStrip™ delivery of caffeine produced
greater bioavailability than standard oral gavage administration.

QuickStrip™ Caffeine Produces Reliable
Increases in Behavioral Arousal

To confirm the effectiveness of QuickStrip™ caffeine delivery
using a functional outcome in mice, we assessed stimulatory
effects on locomotion in the open field. Moderate doses of caffeine
are well-known to produce locomotor stimulation in mice (El
Yacoubi et al., 2000; Karcz-Kubicha et al., 2003), as well as in
humans (Swerdlow et al., 1986; Orrú et al., 2013). We selected a
dose of 20 mg kg-1, which has been used in mice to produce robust
locomotor stimulation and is below the high doses of caffeine that
cause locomotor suppression (100 mg kg-1; El Yacoubi et al., 2000).
Naive C57Bl6 mice were administered 20 mg kg-1 caffeine via either
standard oral gavage or QuickStrip™ (or vehicle control gavage)
and placed in the open-field arena. Mice were allowed to move
freely in the open field for 1 h. The representative paths and heat
maps for gavage and QuickStrip™ caffeine delivery show a high
level of locomotor activity in comparison to the vehicle control
(Figures 2A, B). Analysis of distance traveled over time in the
open field demonstrated that QuickStrip™ caffeine (least square
mean = 21.632 m) produces robust locomotor activation that lasts
the duration of the task, similar to an equal dose of gavage caffeine
(least square mean = 21.234 m; Figure 2C). Both QuickStrip™ and
gavage caffeine-administered mice were more active than vehicle
control mice (least square mean = 18.833 m), with significantly
greater distance traveled at both 50 (QuickStrip™ versus vehicle,
p = 0.038; gavage versus vehicle, p = 0.044) and 60 (QuickStrip™
versus vehicle, p = 0.002; gavage versus vehicle, p = 0.017) min of
the open-field test. Assessment of the average cumulative distance

RESULTS
Rapid Delivery of Caffeine With Quickstrip™
Compared to Standard Oral Gavage

Sublingual delivery via the QuickStrip™ film substrate has the
potential to more rapidly deliver active ingredients compared to
standard oral administration. To quantitatively assess this, we
administered 20 mg kg-1 caffeine to C57Bl6 mice via standard oral
gavage or QuickStrip™ and performed cardiac puncture to obtain
blood samples at 1, 5, 10, 30, and 60 min following administration
(Figure 1A). Serum samples were prepared from whole blood and
analyzed by HPLC to obtain caffeine concentration values. We
compared caffeine concentration values obtained with gavage and
QuickStrip™ caffeine and found that at 1 min, significantly greater
caffeine concentration (3,034.600 ± 408.372 ng/ml) was detected
in the serum when caffeine was delivered to mice via QuickStrip™
compared to gavage (1,677.440 ± 234.864 ng ml-1; p = 0.0102;
Figure 1B). We also found that QuickStrip™ caffeine resulted in
higher serum concentrations at 10 (9,304.200 ± 622.393 ng ml-1)
and 30 (16,776.000 ± 1,708.366 ng ml-1) min postadministration
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FIGURE 1 | HPLC analysis of serum caffeine concentration following administration of 20 mg kg-1 caffeine via QuickStrip™ or gavage. (A) Visual representation of
the experimental design, showing two administration methods (QuickStrip™ or gavage) with five time points where serum was extracted. (B) Box plot comparing
caffeine concentration in the serum at 1 min following gavage or QuickStrip™ administration. (C) Box plot comparing caffeine concentration in the serum at 5 min
following gavage or QuickStrip™ administration (ns, not significant; p = 0.0950). (D) Box plot comparing caffeine concentration in the serum at 10 min following
gavage or QuickStrip™ administration. (E) Box plot comparing caffeine concentration in the serum at 30 min following gavage or QuickStrip™ administration.
(F) Box plot comparing caffeine concentration in the serum at 60 min following gavage or QuickStrip™ administration. p values were calculated using t-test to
compare means. (G, H) Scatter plots showing the concentration of caffeine in serum across all time points for gavage and QuickStrip™, respectively. (I) Comparison
of the AUC between gavage and QuickStrip™. AUC was calculated using SigmaPlot for each scatterplot.

(Figure 2D) reveals that both gavage (127.401 ± 5.300 m) and
QuickStrip™ (129.793 ± 4.845 m) caffeine produce stimulatory
effects on locomotion (p = 0.004; p = 0.005). Additional assessment
of average speed (Figure 2E) also shows that both gavage (0.0355 ±
0.00145 m s-1) and QuickStrip™ (0.0362 ± 0.00136 m s-1) caffeine
produce stimulatory effects on locomotion (p = 0.003; p = 0.004).
In addition to administration to naive mice in the open field, we
also compared the effects of QuickStrip™ and gavage caffeine after
prior exposure to the open-field environment. When first placed
in a novel environment, animals experience heightened activity
levels that decline over time spent exploring the environment,
an effect referred to as habituation (Deacon, 2006). Because of
the effect of the novel environment, all groups of mice are highly
mobile and travel a relatively large distance. To further compare
the routes of administration, we eliminated the effect of the novel
environment by first habituating naive mice to the open field before

Frontiers in Pharmacology | www.frontiersin.org

administration of caffeine via QuickStrip™ or gavage. Analysis of
distance traveled over time in the open field following habituation
and administration demonstrated that QuickStrip™ caffeine (least
square mean = 8.773 m) produces a response similar to an equal
dose of gavage caffeine (least square mean = 9.273 m; Figure
2F). There was a significant interaction between caffeine route of
administration and time, with QuickStrip™ producing an elevated
effect after 35 min. This second phase of enhanced behavioral
arousal may be reflective of the second rise in serum concentration
observed following QuickStrip™ administration of caffeine. The
average cumulative distance traveled (Figure 2G; QuickStrip™:
94.856 ± 8.963 m; gavage: 83.635 ± 14.921 m) and average speed
(Figure 2H; QuickStrip™: 0.0292 ± 0.00245 m s-1; gavage: 0.0248 ±
0.00641 m s-1) did not differ between QuickStrip™ and gavage
caffeine. The behavioral results demonstrated that QuickStrip™
caffeine produces robust locomotor activation similar to that
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FIGURE 2 | Stimulation of locomotion in the open-field test following administration of 20 mgkg-1 of caffeine via either QuickStrip™ or gavage. (A) Representative
paths of animals treated with vehicle (distilled H2O gavage, left), gavage (middle), and QuickStrip™ (right). (B) Representative heat maps showing animal dwell time
in the open-field apparatus with warmer colors indicating longer dwell time. (C) A plot of average distance traveled over time after administration of 20 mg kg-1
caffeine via gavage or QuickStrip™ compared to vehicle control. (* vehicle vs gavage p = 0.044; vehicle vs QuickStrip™ p = 0.038; **vehicle vs gavage p = 0.017;
vehicle vs QuickStripTM p = 0.002). (D) Bar plot of total distance traveled during the 60 min testing period. (E) Bar plot describing the average velocity throughout
the 60 min testing period. (F) A plot of average distance traveled over time when mice were habituated to the open field followed by administration of 20 mg kg-1
caffeine via gavage or QuickStrip™ (**40 min p = 0.016; 45 min p = 0.020). (G) Bar plot of total distance traveled during the 60 min testing period after mice were
habituated to the open field. (ns p = 0.277). (H) Bar plot describing the average velocity throughout the 60 min testing period after mice were habituated to the open
field. (ns p = 0.288). Mean ± standard error, p values were calculated using repeated measures (C, F) or one-way ANOVA (D, E, G, H) in SigmaPlot.

found with gavage oral administration, which is consistent with
the expected effects of moderate doses of caffeine.

EEG is well-known to provide a readout of central nervous system
activity, and specific changes in the EEG follow administration of
different classes of drugs. Caffeine has previously been shown to
suppress low-frequency oscillations, particularly delta (δ) band
activity (Landolt et al., 1995; Landolt et al., 2004; Paterson et al.,
2009). The EEG suppression induced by caffeine is evident from
the raw traces (Figure 3A). Fast-Fourier transform analysis reveals
potent suppression in low-frequency oscillations resulting from
both gavage and QuickStrip™ caffeine delivery (Figure 3B).

More Rapid Effects on the Central Nervous
System With QuickStrip™ Caffeine as
Assessed by Electroencephalography

To sensitively examine the onset of central nervous system effects
following either gavage or QuickStrip™ caffeine, we used EEG.
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To analyze in more detail, we parsed the EEG into spectral
frequency bands δ-0.5–4.0 Hz, θ-4.5–8 Hz, α-8.5–13 Hz, β-13.5–
30, γ-30.5–100 Hz (Drinkenburg et al., 2015) and compared
spectral frequencies between 1 h of baseline and 1 h following
either gavage or QuickStrip™ caffeine delivery. We found that
δ power was significantly suppressed by caffeine as delivered by
gavage (difference of means = 41.497; p < 0.001) and QuickStrip™
(difference of means = 16.336; p < 0.001) compared to baseline
(Figure 3C). θ band power was also significantly suppressed
by both gavage (difference of means = 23.982; p < 0.001) and
QuickStrip™ (difference of means = 12.223; p = 0.015) caffeine.
To assess how rapidly the suppression took place, we measured the
time from drug administration to first suppressed peak, as marked
by a change in power of greater than 2 standard deviations from
the mean baseline (Figure 3D). We found that caffeine delivery by
QuickStrip™ produced suppression of the EEG more rapidly than
gavage delivery, with average onsets of suppression of 1.038 min
and 8.249 min, respectively (p < 0.001; Figure 3E). These data

demonstrated that QuickStrip™ caffeine produced the expected
effects of low-frequency EEG suppression, with a more rapid onset
compared to gavage.

DISCUSSION
In these studies, we used HPLC analysis of mouse serum to
demonstrate that QuickStrip™ delivered the active ingredient
caffeine more rapidly and with greater bioavailability as compared
to gavage administration. We have also shown that QuickStrip™
caffeine produced the expected behavioral effects of locomotor
stimulation, consistent with gavage administration of caffeine.
Quantitative EEG studies demonstrated that QuickStrip™ caffeine
produced rapid central nervous system effects, suppressing lowfrequency EEG more rapidly than gavage. Collectively, these data
demonstrated that the QuickStrip™ delivery substrate may be a
viable option to balance ease of use with rapid delivery.

FIGURE 3 | Electroencephalographic analysis comparing the administration of 20 mg kg-1 caffeine via Quickstrip™ and gavage. (A) Two-hour raw traces, with the
first hour as awake baseline and second with administration of caffeine using gavage or Quickstrip™, marked at the red dotted line. (B) Cumulative Fast Fourier
Transform (cFFT) analysis of EEG data, normalized to baseline. (C) Bar graph showing mean normalized power, separated by frequency band δ-0.5–4.0 Hz,
θ-4.5–8 Hz, α-8.5–13 Hz, β-13.5–30, γ-30.5–100 Hz. (D) Representative 10-s trace of delta power observed after administration via either gavage or Quickstrip™
(time of administration marked by the dotted red line). (E) Bar graph comparing average time for observed delta suppression to occur. Mean ± standard error, p
values were calculated using repeated measures (B, C) or one-way ANOVA (E) in SigmaPlot.
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Serum data revealed rapid absorption of QuickStrip™ caffeine
compared to gavage, with substantial concentrations of caffeine
detected within 1 min of QuickStrip™ delivery. The greatest
variability is observed within the QuickStrip™ caffeine group at the
5-min time point following administration. This variability could
be caused by individual differences in salivation, with high rates
of salivation increasing the pH of the oral cavity and potentially
influencing absorption (Rathbone et al., 1994; Madhav et al., 2009;
Gittings et al., 2015). Also of interest is the second peak in serum
caffeine concentration observed at 30 min following QuickStrip™
delivery, again with higher variance. This may have also resulted
from saliva flow in the individual subjects, which can lead to
swallowing before absorption via the oral mucosa is complete (Patel
et al., 2011). The second peak may allow for longer duration of
effect and may be a desirable component of QuickStrip™. Analysis
of AUC demonstrates increased bioavailability of caffeine when
delivered by QuickStrip™ as compared to gavage. Collectively, the
analysis of HPLC serum caffeine studies reveals that QuickStrip™
provides more rapid and greater overall absorption of an active
ingredient into the blood supply.
QuickStrip™ and gavage caffeine delivery both produced
behavioral activation in the mice, as demonstrated by increased
locomotion in the open field. Given the rapid absorption and greater
bioavailability of QuickStrip™ caffeine, one might have expected
more rapid and robust effects on locomotion. However, behavioral
assessment in the open field does not allow for examination of rapid
onset of locomotor effects because of the high level of activity of
all mice when placed in the novel environment of the open field.
There may also be a “ceiling” to the level of locomotor activation
occurring between 12.5 and 25 mg kg-1, as higher doses of caffeine
do not produce activation (50 mg kg-1) and can produce suppression
of locomotor activity (El Yacoubi et al., 2000). Overall, these
experiments demonstrate that QuickStrip™ caffeine produced the
expected locomotor activation in the open field.
QuickStrip™ caffeine produced rapid suppression of EEG,
which mirrored the serum data. Previous studies in humans and
in nonhuman animals have demonstrated that caffeine suppresses
power particularly in the lower frequencies (Landolt et al., 1995,
Landolt et al., 2004; Paterson et al., 2009; Van Dort et al., 2009).
The effects of suppressing EEG and increasing locomotor activity
are interrelated, stemming from caffeine’s antagonistic action
on adenosine A1 and A2 receptors and downstream regulation
of acetylcholine release (Van Dort et al., 2009). In particular, it
is proposed that A1 receptors within the prefrontal cortex are
involved in descending inhibition of wakefulness (Van Dort et al.,
2009), and consequently, when A1 receptors are inhibited by
caffeine, increased vigilance or arousal results. Arousal from sleep
to wake alone is not sufficient to explain the suppression of EEG
δ-power following caffeine administration because mice were not
allowed to sleep during baseline recordings. Whereas the EEG
suppression appears more apparent in the gavage caffeine-treated
mice, the relationship between dose and/or serum concentration
and EEG effects is not always linear. A higher dose producing a
greater serum concentration may lead to a reversal of a lower dose
effect, analogous to the behavioral response to caffeine, which at
low to moderate doses produce behavioral activation, whereas at
high doses, it produces behavioral arrest (El Yacoubi et al., 2000).
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Using EEG, we were able to detect robust suppression of the EEG
power approximately 1 min following caffeine administration via
QuickStrip™, indicating that caffeine rapidly entered the nervous
system to exert these effects. By comparison, we found that gavage
administration resulted in suppression at approximately 8 min. The
EEG data reflected the rapid absorption of QuickStrip™ caffeine
that was also demonstrated with HPLC assessment of caffeine
concentration in the serum. Paired with the serum data, these
EEG studies demonstrated that QuickStrip™ caffeine is rapidly
absorbed, permitting rapid access to the nervous system. This
result is particularly significant, as access to the central nervous
system is a key factor in the efficacy of psychoactive therapies. The
blood–brain barrier restricts access to the central nervous system,
preventing exposure to dangerous substances, but also limiting
the efficacy of many compounds. The ability of caffeine delivered
via QuickStrip™ to be absorbed into the serum and impact brain
activity rapidly suggests that this route of administration may offer
advantages, particularly for psychoactive compounds.
Caffeine has clinical application in the treatment of headache
and is routinely used alone or in combination with other
treatments by headache patients (Fried et al., 2017; Lipton et al.,
2017). Combinations including caffeine significantly improve the
efficacy of analgesic medication monotherapy for the treatment of
patients with tension headache or migraine (Diener et al., 2014;
Goldstein et al., 2014). Additional benefit has been suggested with
rapid delivery, such as with the use of intravenous administration
of caffeine (Baratloo et al., 2017); however, for many patients,
this route of administration is impractical. QuickStrip™ caffeine
may provide convenient yet more rapid delivery than an orally
administered analgesic that includes caffeine. Again, being able
to rapidly act on the brain is a particular benefit, as the rapid
alleviation of symptoms is desirable and limits secondary aspects
of headache and migraine from developing. A thin, rapidly
dissolving film delivered to the oral mucosa also offers advantages
over oral tablets in terms of convenience and may offer improved
patient comfort and compliance (Reiner et al., 2010). In summary
QuickStrip™ offers both rapid and functional delivery of caffeine,
with greater bioavailability and more rapid central nervous
system effects compared to standard oral administration. Further
development of micronized dispersions of therapeutics for buccal
and sublingual administration will advance available options for
patients and has the potential to improve health outcomes.
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